RVMD Insider Trading

Insider Ownership Percentage: 8.00%
Insider Buying (Last 12 Months): $59,999,962.00
Insider Selling (Last 12 Months): $10,871,731.20

Revolution Medicines Insider Trading History Chart

This chart shows the insider buying and selling history at Revolution Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Revolution Medicines Share Price & Price History

Current Price: $42.34
Price Change: Price Increase of +0.87 (2.10%)
As of 02/19/2025 05:00 PM ET

This chart shows the closing price history over time for RVMD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFeb$42.34Closing price on 02/19/25:

SEC Filings (Institutional Ownership Changes) for Revolution Medicines (NASDAQ:RVMD)

94.34% of Revolution Medicines stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RVMD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.22Bbought$160MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Revolution Medicines logo
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More on Revolution Medicines

Today's Range

Now: $42.34
Low: $41.22
High: $42.37

50 Day Range

MA: $42.70
Low: $39.83
High: $46.43

52 Week Range

Now: $42.34
Low: $28.43
High: $62.40

Volume

733,642 shs

Average Volume

1,291,792 shs

Market Capitalization

$7.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Who are the company insiders with the largest holdings of Revolution Medicines?

Revolution Medicines' top insider shareholders include:
  1. Thilo Schroeder (Director)
  2. Mark A Goldsmith (Insider)
  3. Stephen Michael Kelsey (Insider)
  4. Margaret A Horn (COO)
  5. Jack Anders (CFO)
  6. Margaret A Horn (Insider)
  7. Jeff Cislini (General Counsel)
  8. Sushil Patel (Director)
  9. Barbara Weber (Director)
Learn More about top insider investors at Revolution Medicines.

Who are the major institutional investors of Revolution Medicines?

Revolution Medicines' top institutional investors include:
  1. Vanguard Group Inc. — 10.16%
  2. Farallon Capital Management LLC — 7.88%
  3. Wellington Management Group LLP — 6.43%
  4. Janus Henderson Group PLC — 5.64%
  5. Baker BROS. Advisors LP — 4.72%
  6. Nextech Invest Ltd. — 4.52%
Learn More about top institutional investors of Revolution Medicines stock.

Which institutional investors are selling Revolution Medicines stock?

Within the last quarter, RVMD stock was sold by these institutional investors:
  1. Wellington Management Group LLP
  2. Soleus Capital Management L.P.
  3. Bellevue Group AG
  4. Casdin Capital LLC
  5. Fred Alger Management LLC
  6. Balyasny Asset Management L.P.
  7. Avidity Partners Management LP
  8. Alphabet Inc.
In the last year, company insiders that have sold Revolution Medicines company stock include:
  1. Thilo Schroeder (Director)
  2. Mark A Goldsmith (Insider)
  3. Stephen Michael Kelsey (Insider)
  4. Margaret A Horn (COO)
  5. Jack Anders (CFO)
  6. Margaret A Horn (Insider)
  7. Jeff Cislini (General Counsel)
Learn More investors selling Revolution Medicines stock.

Which institutional investors are buying Revolution Medicines stock?

In the last quarter, RVMD stock was purchased by institutional investors including:
  1. Boxer Capital Management LLC
  2. Janus Henderson Group PLC
  3. Vanguard Group Inc.
  4. Farallon Capital Management LLC
  5. Norges Bank
  6. Nextech Invest Ltd.
  7. Paradigm Biocapital Advisors LP
  8. FMR LLC